Conventional tuberculosis (TB) diagnosis is time-consuming, while newer molecular assays such as Xpert MTB/RIF and loop-mediated amplification test for TB (TB-LAMP) provide faster results but at a higher cost compared to sputum smear microscopy (SSM) with culture and drug susceptibility testing (DST) in Thailand. This study assessed the cost-utility of TB diagnostic algorithms as either initial or add-on tests from a societal perspective for TB diagnosis in the general Thai population. A dynamic transmission model was employed to evaluate five TB diagnostic algorithms over a 15-year period. Costs were calculated in 2023 Thai Baht, with results presented as incremental cost-effectiveness ratios (ICERs) compared to SSM with culture and DST. One-way and probability sensitivity analyses were conducted to assess parameter uncertainty. Compared to SSM with culture and DST, the ICER values (Baht per QALY gained) of TB-LAMP Add-On (3,563), Xpert MTB/RIF Add-On (3,670), and TB-LAMP Initial (6,429) indicated that these algorithms were cost-effective, while Xpert MTB/RIF Initial emerged as a cost-saving option. One-way sensitivity analysis results revealed that the utility of the first-line treatment exhibited the highest variability in ICERs, followed by the unit cost of Xpert MTB/RIF. The results supported the adoption of Xpert MTB/RIF as an initial test for the general Thai population. These findings provide evidence for policymakers to integrate molecular testing into Thailand's Universal Coverage Scheme benefit package, aligning with national TB strategies to reduce TB incidence and mortality.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875360 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0315772 | PLOS |
Lancet Infect Dis
March 2025
South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Background: People with tuberculosis who complete treatment remain at risk of recurrent disease. The vaccine H56:IC31 has been shown to be safe and immunogenic in phase 1 and 2 studies, but whether it can reduce the risk of tuberculosis recurrence is unknown.
Methods: In a double-blind, randomised, placebo-controlled, phase 2b trial in South Africa (five clinical trial sites) and Tanzania (one clinical trial site), we enrolled participants aged 18-60 years, without HIV, who had completed more than 5 months (22 weeks) of treatment for drug-susceptible pulmonary tuberculosis.
Open Forum Infect Dis
March 2025
Tropical Medicine and International Health Unit, Infectious Diseases Department, Vall Hebron University Hospital, Barcelona, Spain.
Systematic screening of tuberculosis (TB) using molecular testing on stool samples detected TB in 5.2% of acutely malnourished children, including cases without evident clinical symptoms. This screening strategy could enhance TB diagnosis and facilitate prompt treatment initiation in this population.
View Article and Find Full Text PDFRes Sq
February 2025
DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Introduction: Non-sputum tests for people attending primary care with symptoms of tuberculosis (TB) are a global priority.
Methods: We performed a cross-sectional two-centre diagnostic accuracy study of a next-generation urine lipoarabinomannan assay (Biopromic TB LAM, BP-LAM) and the lateral flow Determine TB LAM Ag assay (LF-LAM) on urine from 629 adults with presumptive pulmonary TB (315 with TB) attending primary care in South Africa and Uganda. An extended sputum microbiological reference standard (eMRS) was used and, in South Africa, sputum induction done.
PLoS One
March 2025
Social Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Conventional tuberculosis (TB) diagnosis is time-consuming, while newer molecular assays such as Xpert MTB/RIF and loop-mediated amplification test for TB (TB-LAMP) provide faster results but at a higher cost compared to sputum smear microscopy (SSM) with culture and drug susceptibility testing (DST) in Thailand. This study assessed the cost-utility of TB diagnostic algorithms as either initial or add-on tests from a societal perspective for TB diagnosis in the general Thai population. A dynamic transmission model was employed to evaluate five TB diagnostic algorithms over a 15-year period.
View Article and Find Full Text PDFIn 2020, fecal (stool) testing was recommended for diagnosing Mycobacterium tuberculosis complex (MTBC) infection in children by using the Cepheid Xpert MTB/RIF assay; since then, countries have begun implementing stool-based testing, often as part of a comprehensive strategy to enhance TB case finding among children. On the basis of an experience-sharing workshop in November 2023, we determined insights of 9 early-adopter countries. Across those countries, 71,757 children underwent stool testing over a combined period of 121 months, October 2020-September 2023.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!